Herman, W.H., Braffett, B.H., Kuo, S., Lee, J.M., Brandle, M., Jacobson, A.M., Lisa A. and Lachin, J.M. (2018) The 30-Year Cost-Effectiveness of Alternative Strategies to Achieve Excellent Glycemic Control in Type 1 Diabetes: An Economic Simulation Informed by the Results of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Journal of Diabetes and its Complications, 32, 934-939.
https://doi.org/10.1016/j.jdiacomp.2018.06.005

has been cited by the following article:

• TITLE: Long Term Benefit of Autologous Bone Marrow Stem Cell Transplantation without Immunosuppression in Chronic Type 1 Diabetic Patients

  AUTHORS: Alejandro Mesples, Yun Zhang, Xiang Hu

  KEYWORDS: Type 1 Diabetes, Bone Marrow Transplantation, Bone Marrow Stem Cells

  JOURNAL NAME: Stem Cell Discovery, Vol.10 No.1, January 30, 2020

  ABSTRACT: Background:Autologous bone marrow stem cell transplantation without immune suppression has been proposed as a safe and efficient therapeutic option to replace β-cell mass destroyed by specific antibodies in chronic type 1 diabetes but we have not scientific information about how long the metabolic stability is maintained. Material and Method: From 2010 to 2014, were included 134 chronic type 1 diabetics patients (p.) in an autologous bone marrow stem cell transplantation protocol, stimulated with filgrastim, without immune suppression, c peptide Results:C peptide, 6 months after transplantation more than 0.9 ng/ml in 61 patients (45%) (P = 0.001, CI = 95%). At 12 months 50 patients (37%) (P = 0.001, CI = 95%). At 24 months 53 patients (39%) (P = 0.001, CI = 95%). At 36 months 51 patients (38%) (P = 0.001, CI = 95%). A1C before transplant, Conclusion:Autologous bone marrow stem cell transplantation, without immunosuppression, improves pancreatic function and metabolic control without new immune reaction after three years of follow up in chronic type 1 diabetic patients.